Legal & General Group Plc Invests $2.74 Million in Collegium Pharmaceutical, Inc. $COLL

Legal & General Group Plc purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 75,576 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,736,000.

Several other hedge funds have also added to or reduced their stakes in COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical in the fourth quarter worth about $28,000. Caitong International Asset Management Co. Ltd lifted its position in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. lifted its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at about $61,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $23.53 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $766.14 million, a P/E ratio of 18.98 and a beta of 0.72. The business has a 50-day moving average of $31.86 and a 200-day moving average of $34.30. Collegium Pharmaceutical, Inc. has a 1 year low of $23.37 and a 1 year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The business had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same period last year, the company posted $1.68 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Piper Sandler reiterated a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Barclays lowered their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, August 19th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.